Universal Beteiligungs und Servicegesellschaft mbH Invests $12 Million in Exelixis, Inc. (NASDAQ:EXEL)

Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 360,292 shares of the biotechnology company’s stock, valued at approximately $11,998,000.

A number of other hedge funds have also modified their holdings of EXEL. Vanguard Group Inc. grew its stake in Exelixis by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock worth $979,994,000 after acquiring an additional 121,750 shares during the period. LSV Asset Management grew its stake in Exelixis by 0.8% in the 4th quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock worth $272,056,000 after acquiring an additional 67,470 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in Exelixis by 10.2% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company’s stock worth $254,110,000 after acquiring an additional 708,312 shares during the period. Invesco Ltd. grew its stake in Exelixis by 308.1% in the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after acquiring an additional 3,001,204 shares during the period. Finally, AQR Capital Management LLC grew its stake in Exelixis by 25.7% in the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company’s stock worth $132,101,000 after acquiring an additional 810,857 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 126,383 shares of Exelixis stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the sale, the executive vice president now owns 446,459 shares of the company’s stock, valued at $21,412,173.64. The trade was a 22.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the sale, the executive vice president now directly owns 693,181 shares in the company, valued at $27,034,059. This trade represents a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 441,740 shares of company stock worth $20,282,998. 2.82% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have commented on EXEL shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $47.00 target price (up from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. Barclays lifted their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Thursday, March 27th. Stifel Nicolaus lifted their target price on shares of Exelixis from $36.00 to $38.00 and gave the stock a “hold” rating in a research note on Wednesday, May 14th. Finally, Wall Street Zen lowered shares of Exelixis from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 15th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.94.

Exelixis Trading Up 0.5%

NASDAQ:EXEL opened at $42.81 on Friday. The firm has a market capitalization of $11.67 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 1.13 and a beta of 0.25. The firm’s fifty day simple moving average is $38.45 and its 200 day simple moving average is $36.37. Exelixis, Inc. has a twelve month low of $21.18 and a twelve month high of $48.85.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.